OncoMatch/Clinical Trials/NCT06869213
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
Is NCT06869213 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin for esophageal cancer (esc).
Treatment: Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin — This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined with nab-paclitaxel and cisplatin preoperatively and adebrelimab (SHR-1316) single-agent adjuvant therapy postoperatively, to observe the efficacy and safety of this treatment modality, and to provide clinical evidence for the use of PD-L1 monoclonal antibody in perioperative treatment of esophageal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-CT2, N+, CT3-CT4A, ANY N (AJCC 8th edition)
pre-treatment clinical stage cT1b-cT2, N+ or cT3-cT4a, ANY N according to the 8th edition of AJCC staging
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy
Cannot have received: radiotherapy
No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy
Cannot have received: hormone therapy
No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy
Cannot have received: immunotherapy
No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L; WBC ≥ lower limit of laboratory normal; ANC ≥ 1.5 × 10^9/L; Platelet count ≥100×10^9/L
Kidney function
Creatinine ≤ 1.5 x ULN and Cr clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN; Prothrombin time ≤ 16 seconds and INR ≤ 1.5 x ULN
laboratory tests to confirm that bone marrow, liver and kidney function meet the requirements for participation in the study (requiring no blood transfusion or use of hematopoietic stimulating factors (including G-CSF, GM-CSF , EPO, and TPO, etc.) within 14 days prior to screening): * Hemoglobin ≥ 90 g/L; * White blood cell count ≥ lower limit of laboratory normal; * Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; * Platelet count ≥100×10^9/L; * Total bilirubin ≤ 1.5 x upper limit of normal (ULN); * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN; * Prothrombin time ≤ 16 seconds and International Normalized Ratio (INR) ≤ 1.5 x ULN; * Creatinine ≤ 1.5 x ULN and Cr clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify